Search

Introduction: Cervical cancer is a severe malignant tumor that endangers the health of women worldwide. Eukaryotic initiation factor-5A2 (EIF5A2) expression has been reported to be increased in cervical cancer and correlates with prognosis. An attempt was made in this paper to explore the impact and potential mechanisms of EIF5A2 in the cell biology of cervical cancer. Methods: We first knocked down EIF5A2 in cervical cancer cells. Then, we examined the proliferation, migration, invasion, and apoptosis of these cells by cell counting kit 8, wound healing, Transwell, and terminal deoxynucleotidyl transferase dUTP nick-end labeling assays. Cells were processed with different concentrations of cisplatin to observe their sensitivity to cisplatin. Next, the relationship between EIF5A2 and anterior gradient 2 (AGR2) was verified by co-immunoprecipitation. Following AGR2 overexpression, the biological processes of these cells were examined. Results: EIF5A2 knockdown inhibited cell proliferation, migration, and invasion, and it promoted apoptosis and enhanced the sensitivity to cisplatin in cervical cancer cells. Additionally, AGR2 expression was positively correlated with EIF5A2, and its overexpression alleviated the reduction in proliferation, migration, and invasion of cervical cancer cells induced by EIF5A2 knockdown. Overexpression of AGR2 also reduced apoptosis and their sensitivity to cisplatin in EIF5A2-knockdwon cervical cancer cells. Conclusion: EIF5A2 knockdown inhibited the biological process of cervical cancer cells through modulation of AGR2. The in-depth investigation of the molecular mechanism of EIF5A2 in cervical cancer cells provides new strategies for the prevention and treatment of clinical malignancies. [ABSTRACT FROM AUTHOR]

Objective: To study the antihypertensive effects of the angiotensin-converting enzyme (ACE)-inhibitory peptide LAP on blood pressure in spontaneously hypertensive rats (SHRs). Methods: A cohort of 12-week-old SHRs was randomly divided into 2 distinct groups, and ACE-inhibitory peptide LAP (experimental group) or physiological saline (controls) were administered. Caudal arterial blood pressure was then measured at specific time points (0, 4, 8 and 12 weeks). Results: Systolic blood pressure of the SHRs showed a significant decrease after intraperitoneal injection with the ACE-inhibitory peptide LAP. Moreover, this depressurization effect lasted for over 1 month. Conclusion: Systolic blood pressure of SHRs could effectively be depressed in the long term by antihypertensive activity mediated by the ACE-inhibitory peptide LAP. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]